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Abstract
Purpose
Combined ultrafast 90˚+90˚ kV-MV-CBCT within single breath-hold of 15s has high clinical
potential for accelerating imaging for lung cancer patients treated with deep inspiration
breath-hold (DIBH). For clinical feasibility of kV-MV-CBCT, dose exposure has to be small
compared to prescribed dose. In this study, kV-MV dose output is evaluated and compared
to clinically-established kV-CBCT.
Methods
Accurate dose calibration was performed for kV and MV energy; beam quality was deter-
mined. For direct comparison of MV and kV dose output, relative biological effectiveness
(RBE) was considered. CT dose index (CTDI) was determined and measurements in vari-
ous representative locations of an inhomogeneous thorax phantom were performed to simu-
late the patient situation.
Results
A measured dose of 20.5mGE (Gray-equivalent) in the target region was comparable to
kV-CBCT (31.2mGy for widely-used, and 9.1mGy for latest available preset), whereas kV-
MV spared healthy tissue and reduced dose to 6.6mGE (30%) due to asymmetric dose dis-
tribution. The measured weighted CTDI of 12mGE for kV-MV lay in between both clinical
presets.
Conclusions
Dosimetric properties were in agreement with established imaging techniques, whereas
exposure to healthy tissue was reduced. By reducing the imaging time to a single breath-
hold of 15s, ultrafast combined kV-MV CBCT shortens patient time at the treatment couch
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and thus improves patient comfort. It is therefore usable for imaging of hypofractionated
lung DIBH patients.
Introduction
Image-guided radiotherapy (IGRT) enabled dose escalation to limited volumes and at the
same time a reduction of normal tissue complications in external-beam-radiotherapy (EBRT)
and stereotactic-body-radiotherapy (SBRT) [1,2]. The most commonly used technique for
pre-treatment imaging is a perpendicularly mounted kilovoltage- (kV) Cone-Beam Computed
Tomography (kV-CBCT) [3–5] while Megavoltage- (MV) treatment beam has only been used
on a limited basis as MV-CBCT [6,7] due to reduced soft-tissue contrast and reduced quantum
efficiency.
An approach increasingly employed to reduce for lung and liver motion is to treat the
patient during computer-controlled breath-hold (deep-inspiratory breath-hold, DIBH) [8].
While the radiation treatment can now be performed within only a few breath-holds, CBCT
image acquisition in repeated breath-hold takes about 3-4min. Although this “start/stop”
CBCT imaging approach in combination with multiple breath-holds results in images of excel-
lent image quality [9,10], it considerably extends the imaging time into the range of flattening
filter free treatment delivery [11,12]. CBCT image acquisition within one single breath-hold
(typically 10-20s) would result in high treatment precision with dramatically shortened overall
treatment times while significantly increasing patient comfort.
Our novel imaging technique of combined ultrafast kV-MV-CBCT performs image acqui-
sition within one breath-hold of 15s [13,14]. KV-MV-CBCT is based on the initial step-and-
shoot technique introduced by Yin et al. [15], but was fully developed by us to be performed
dynamically to be completed within 15s, which is a prerequisite for clinical implementation.
KV-MV-CBCT is realized by simultaneous image acquisition of 90˚ kV and 90˚ MV projec-
tions, resulting in 180˚ image information (+ cone-angle). It can be operated on a clinically
commissioned linear accelerator (Elekta Synergy linac) with minimal modifications [14]. The
development of kV-MV-CBCT is finalized, the workflow is fully automated [16] and the
image acquisition as well as image registration can be performed in real-time [17].
For the implementation of kV-MV-CBCT into clinical routine, imaging dose exposure to
the patient has to be investigated and compared to clinically-established techniques. A stan-
dard dose value for a kV-MV-CBCT preset has to be defined for future quality assurance and
documentation. We performed a comparison of imaging dose applied with kV-CBCT stan-
dard presets currently used in clinical routine. First, a lung tumor patient was simulated with
an inhomogeneous thorax phantom and the dose exposure was measured at representative
positions. Second, the weighted CT dose index was determined with an appropriate CT phan-
tom. Proper ionization chamber calibration was performed for applied kV and MV energies,
as well as the relative biological effectiveness was considered.
Methods
KV-MV-CBCT imaging was developed on a clinical 6MV Elekta Synergy linac (Integrity
v1.2), equipped with a foldout MV detector (iView GT v3.4) and a perpendicularly mounted
kV-CBCT-system (XVI v4.2.2). To compare kV-MV-CBCT with clinically-established tech-
niques, not only the Chest-preset of the Elekta Synergy linac was applied in the phantom dose
measurements but also the Chest-preset of the latest available kV-CBCT software version (XVI
v5.0.2), installed on a clinical Elekta VersaHD linac (all Elekta AB, Stockholm, Sweden).
Evaluation of kV-MV-CBCT dose exposure
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Setup of conventional kV-CBCT and kV-MV-CBCT
The imaging dose outputs of the following three imaging techniques were compared in this
study (technical setups are summarized in Table 1):
• Clinical kV-Chest1-CBCT
On the Elekta Synergy linac, the still widely-used XVI version 4.2.2 was installed. The preset
routinely applied for lung SBRT was called “kV-Chest1” throughout this study.
• Clinical kV-Chest2-CBCT
The preset “kV-Chest2” of the recently introduced XVI version 5.0.2, installed on the Elekta
VersaHD linac, differed slightly from the previous preset kV-Chest1. A bow-tie filter was
applied and the mAs was reduced, as thus was the nominal scan dose (CT dose per volume).
Acquisition time remained the same (2min); however, beam interruptions were possible in
case of DIBH treatment, extending imaging time to 3-4min.
• kV-MV-CBCT
The kV-MV-CBCT imaging technique was set up as a simultaneous 90˚ kV and 90˚ MV
scan, achieved by dedicated in-house developed synchronization hard- and software. Since
the MV-panel was initially not developed for continuous imaging, linac-pulsing and panel-
readout had to be triggered alternately. Due to limited readout-speed, one MV-projection
could only be acquired with every fifth kV-projection, resulting in 19 MV-projections versus
100 kV-projections for a 90˚ scan (+ cone-angle of 10˚).
Linac-parameters were adjusted with our automated workflow to achieve low-dose output of
4–5 Monitor Units (MU) distributed equally over the 19 MV-projections, depending on
wear of magnetron and electron gun. At the time of this study, the output was 4MU for a
100˚ rotation. Acquired kV- and MV-volumes were reconstructed separately and combined
after appropriate grey-scale matching [13,14,16,17].
Determination of beam quality and dose correction factors
All absorbed dose measurements were corrected following the AAPM TG protocol 61 [18]
(kV-energy range) and the IAEA TPS 398 [19] (MV-energy range). For both energy ranges,
Table 1. Technical setup of applied imaging presets.
Preset kV-Chest1-CBCT kV-Chest2-CBCT kV-MV-CBCT
Output characteristics 120kVp 120kVp kV: 100kVp
1mAs (25mA, 40ms) per frame 0.4mAs (20mA, 20ms) per frame 0.1mAs (10mA, 10ms) per frame
MV: 6MV linac (4MU)
Number of frames 650 660 kV: 100
MV: 19
Panel position off-centered (M) off-centered (M) centered (S)
Filter, F0 (empty), F1 (bow-tie), kV: F0 (empty),
Collimator (field size) M20 (27.67cm x 42.64cm) M20 (27.67cm x 42.64cm) S20 (27.67cm x 27.67cm)
MV: 25cm x 25cm
Rotation speed ½ rpm ½ rpm 1 rpm
Acquisition length 360˚ 360˚ 90˚ + cone angle
(here: 0˚ to 100˚)
Acquisition time 2min minimum 2min 15s
Nominal dose (uncorrected) 16mGy 5mGy kV: 0.02mGy
MV: 4MU
https://doi.org/10.1371/journal.pone.0187710.t001
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measurements were performed with two differently-calibrated air-filled point-dose flexible
cylindrical ionization chambers (Type 31013, 0.3cm3 sensitive volumes) and a UNIDOS E
Universal dosemeter (all PTW Freiburg GmbH, Freiburg, Germany). The first ionization
chamber was calibrated in air kerma for kV-range (50-150kVp), the second ionization cham-
ber was calibrated on absorbed-dose-to-water for 60-Cobalt (MV-range).
The beam qualities and calibration factors for absolute dose measurements in both kV-and
MV-energy ranges are determined as follows.
KV-energy range: Beam quality and correction factors. Following the AAPM TG61 pro-
tocol [18], kV beam qualities for the applied beam setups were characterized by measuring the
half-value-layers (HVL) of aluminum and calibration factors were determined accordingly.
Similar adaptation of the AAPM TG61 protocol for kV-CBCT was performed by Song et al.
[20] in 2008.
KV beam quality–determination of HVL: A self-made collimator with field size (5.5x5.5)
cm2 in the isocenter was used to achieve narrow-beam geometry to minimize scatter effects
[21]. The x-ray source was positioned at 0˚ and the detector was moved out of the field-of-
view (FOV). A measurement stand on top of the treatment couch aligned both the ionization
chamber and the varying aluminum absorbers with the center of the FOV (see Fig 1). The
source to surface distance (SSD) was 100cm for the ionization chamber, the aluminum absorb-
ers were positioned at SSD 50cm. The thickness of the attenuator varied from 0.01–10.31mm,
the purity of aluminum was 99.9%.
The HVL was measured for all 3 presets (kV-Chest1, kV-Chest2 and the kV-contribution of
kV-MV), with slight modifications such as static gantry position and adapted number of
frames. All HVL measurements were normalized. The preset collimators were replaced with
the narrow-beam collimator. To determine the HVL, first, the initial dose output I0 was
Fig 1. HVL measurement setup.
https://doi.org/10.1371/journal.pone.0187710.g001
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measured free in air (take average value from 4 measurements). Thereafter, the thickness of
the aluminum absorbers was increased in different step sizes between 0.01mm and 1.06mm,
and dose output was measured. The step sizes around the I0/2 region were smallest to increase
measurement accuracy around the expected HVL value.
In literature, the HVL is usually calculated under ideal conditions of a monoenergetic x-ray
beam, following the Lambert-Beer-Law:
IðxÞ ¼ I0e
  mx ð1Þ
HVLLB ¼
ln2
m
; for I HVLLBð Þ ¼
I0
2
; ð2Þ
where I(x) is the dose output at depth x in a medium, I0 is the initial dose output in air, and μ
is the attenuation coefficient of the absorber material.
However, in reality, the x-ray tube produces polyenergetic beams (with peak energy kVp).
Inherent beam filtration such as aluminum filters is used for beam hardening, i.e. low-energy
x-rays are filtered, which would be absorbed by the patient’s body and thus not contribute to
imaging but only increase the applied dose to the patient. In 1994, Bjaerngard and Shackford
[22] analyzed this beam hardening effect. They suggested the following mathematical descrip-
tion of a second-order polynomial in thickness, to analyze the transmission characteristics in
terms of varying attenuation coefficient μ and beam-hardening coefficient η:
IðxÞ ¼ I0e
  mxð1  ZxÞ ¼ I0e
  mxþmZx2 ð3Þ
HVLBS ¼
m  
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
m2   4mZln2
p
2mZ
ð4Þ
KV beam quality–correction factors: After calculating the HVL for each imaging preset fol-
lowing [22], the appropriate correction factors could be determined from the look-up-tables
provided in [18], following the dosimetry formalism for tube voltages between 100-300kV:
Dw ¼ MNkPQ;chamPsheath
men
r
 water
air
 
water
ð5Þ
with M = (Mraw −M0)PTPPionPpolPelec
The in-phantom formalism converted the air-kerma calibrated ionization chamber reading
M [C] to absorbed dose-to-water Dw [Gy]. Further explanations about the correction factors
Nk (air-kerma calibration), PQ,cham (ionization chamber stem correction), Psheath (ionization
chamber waterproofing sheath correction),
men
r
 water
air
h i
water
(water-to-air ratio of the mass-
energy-absorption coefficients averaged over the incident photon spectrum), PTP (tempera-
ture-pressure correction), Pion (ion collection efficiency), Ppol (polarity correction) and Pelec
(electrometer correction) can be found in Ma et al. [18].
MV-energy range: Beam quality and correction factors. The determination of MV-
energy beam quality differs from the kV beam quality procedure, because the MV beam is
already hardened by heavy inherent filtration of target and flattening filter. A convenient
method to determine the energy of the MV beam is to measure the percentage depth dose dis-
tribution (PDD) and put it in relation to reference data, i.e. 60-Cobalt.
MV beam quality—determination of quality index Q: Following [19], the PDD was mea-
sured in a water tank and the beam quality index Q of our clinical 6MV Synergy linac beam
was determined. The reference setup was SSD 100cm, field size was 10x10cm2 in isocenter,
Evaluation of kV-MV-CBCT dose exposure
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and the PDD was acquired for a depth of 0-30cm in a water tank (IBA blue phantom, IBA
Dosimetry, Schwarzenbruck, Germany). The ionization chamber was positioned in the central
axis of the beam and corrected for the effective point of measurement.
MV beam quality–correction factors: From the acquired PDD, the percentage dose values
of depths 20cm (M20) and 10cm (M10) can be selected and the beam quality index can be cal-
culated as follows [19]:
Q ¼ 1:2661
M20
M10
  0:0595 ð6Þ
The absorbed dose-to-water calculation for high energy beams (MV-range) follow the for-
malism:
Dw ¼ MND;wkQ ð7Þ
with M = (Mraw −M0)PTPPionPpolPelec
The beam-quality conversion factor kQ converts the calibration factor of the reference
energy (Cobalt-60) to the energy of beam quality Q, and can be found in the look-up-table pro-
vided in IAEA TRS 398 [19]. Further details about the correction factors can be found in litera-
ture [19,23].
Consideration of relative biological effectiveness
The ICRP-60 and ICRP-103 reports [24,25] suggest to keep a uniform radiation weighting
factor of wR = 1 for all low-LET-radiations such as x-rays, electrons and gamma-rays of all
energies. However, several studies discovered an increase in biological effectiveness with
decreasing photon energy [26–28]. These studies are either based on epidemic data of the
Hiroshima and Nagasaki atomic bombs or on in vitro radio-biological measures, and show sig-
nificant differences in biological effectiveness for different energies.
In IGRT, special consideration has to be taken of a potentially increased risk of secondary
cancer [29–31]. In the review of Nikjoo et al. [28], some studies were presented in which the
RBE between low- and high-energy photons were compared. For the biological endpoint of
neoplastic cell transformation, determined RBE-values range from 2 to 4. Hill et al. [26] and
Borek et al. [32] determined an RBE = 2 for low vs. an RBE = 1 for high photon energies.
In this dosimetry study, a conservative RBE ratio of 2:1 for kV vs. MV biological effective-
ness was chosen with regard to secondary cancer risk. MV-dose was then converted to kV-
equivalent dose by reducing the MV-dose by one half and denominated Gray-equivalent [GE].
Dosimetry phantom setup
Dose measurement comparisons between kV-MV-CBCT and other CBCT-presets were per-
formed on two phantoms. First, dose output was measured in several regions of an inhomoge-
neous thorax phantom, to simulate patient imaging dose exposure. Second, a CT dose index
(CTDI) was determined for kV-MV-CBCT and compared to other imaging techniques.
The dose measurements of kV-MV-CBCT were performed separately for kV- and MV-con-
tribution. Since the beam qualities differed, two differently-calibrated ionization chambers had
to be used. This splitting allowed separate evaluation of the dose contributions as well as con-
sideration of RBE to convert MV to kV-equivalent dose, making final absorbed kV-MV dose
exposure comparable to the clinical kV-only CBCT-presets.
Inhomogeneous thorax phantom–patient simulation. The inhomogeneous thorax
phantom (model 002LFC, CIRS, Norfolk, VA, USA) consisted of different materials according
to the human thorax, i.e. mimicking two lungs and a spinal cord. In our study, a target volume
Evaluation of kV-MV-CBCT dose exposure
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was defined in the lower left lung of the phantom. This tumor-mimicking inlay was to be
located in the isocenter (Fig 1(A)). Dose measurements were performed in representative
beam positions of the phantom:
1. tumor in lower left lung
2. left lung
3. right lung
4. upper periphery
5. spinal cord
6. body center
To spare the contralateral lung in analogy to a patient imaging procedure, the kV-MV pre-
set was designed to rotate only on the side of the tumor location, i.e. from gantry position
0–100˚.
The MV-contribution of the kV-MV-CBCT was additionally simulated with the Oncentra
treatment planning system (Elekta Oncentra Masterplan, Elekta AB, Stockholm, Sweden) for a
4MU per 100˚ arc.
CT dose index—QA phantom. Following the quality assurance (QA) protocol of AAPM
reports TG179 [4] and TG75 [33], a standard dose value for regular QA was defined for
kV-MV-CBCT. Many CTDI determination and dose comparison studies between different
CBCT-presets of Elekta and Varian were published in the last years [34–38]. Initially, the
CTDI was developed for diagnostic CT, but with the transmission to CBCT and larger field of
views, the proper use of ionization chamber had to be reconsidered. Dixon et al. [39] suggested
to use a small point-dose ionization chamber measuring the central beam of CBCT, instead of
the commonly used 10cm long ionization chamber.
In our study, the CTDI measurements were performed in the CT body phantom (T40016,
PTW, Freiburg, Germany), made of polymethyl-mathacrylate (PMMA, density ρ = 1.19g/
cm3), with diameter 32cm and axial length 15cm (Fig 2(B)). The phantom featured five cavities
to sequentially insert the ionization chamber: one center and four peripheral positions (at gan-
try angle 0˚, 90˚, 180˚, 270˚). The dose measurements were again performed with the two dif-
ferently-calibrated (kV- and MV-energy) point-dose ionization chambers. An additional
halved dummy plug was placed into the cavities sequentially together with the ionization
chamber at axial midpoint (isocenter) of the phantom to prevent the air gap. The weighted
CTDIw was calculated as follows [33]:
CTDIw ¼
1
3
CTDIc þ
2
3
CTDIp ð8Þ
with CTDIc central dose
and CTDIp ¼
1
4
CTDIp;0 þ CTDIp;90 þ CTDIp;180 þ CTDIp;270
 
ð9Þ
peripheral dose (averaged).
Results
Following the AAPM TG61 protocol (kV-energy) [18] for kV-Chest1, kV-Chest2 and the kV-
contribution of kV-MV-CBCT, and the IAEA TRS 398 protocol (MV-energy) [19] for the
MV-contribution of kV-MV-CBCT, the beam qualities and corresponding calibration factors
Evaluation of kV-MV-CBCT dose exposure
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for dose measurements were determined and applied (see chapter 2.2 and Table 2). Fig 3(A)
shows the HVL measurements and the fit function according to Bjaerngard and Shackford
[22] (goodness of fit R2 = 0.9988–0.9997), the calculated HVLBS matched with our direct mea-
surement results within a 2% maximum difference and was consistent with measurement val-
ues found in literature [18,20,40]. The MV PDD is shown in Fig 3(B).
Inhomogeneous thorax phantom–patient simulation
Column 8 in Table 3 shows the corrected absolute dose output for the various locations (seri-
ally numbered) and imaging methods. The dose measurements of kV-MV-CBCT were per-
formed separately (columns 5 and 7), because the dose responses of kV and MV behaved
differently. Furthermore, the separate dose contributions could be distinguished and the dif-
ferent RBE could be considered (column 6), enabling proper dose comparison in kV-range.
The final absorbed dose of kV-MV-CBCT in column 8 is the sum of the kV-contribution and
the kV-equivalent MV-contribution, the unit is [GE].
Comparison of MV dose measured vs. calculated (TPS). To demonstrate asymmetric
dose distribution of kV-MV-CBCT, the MV-contribution was simulated in the Oncentra TPS.
The axial dose distribution of 4MU equally distributed over 100˚ is shown in Fig 3(C), the cal-
culated MV dose outputs are listed in column 3 of Table 3. In this comparison the RBE was
not considered, i.e. the originally measured absorbed dose was shown. The percentage differ-
ence between measured and calculated MV dose values with a maximum difference of 2.8%
underlined a proper MV dose output also in low-dose mode (column 4 of Table 3).
Dose comparison of kV-MV imaging vs. conventional CBCT. Column 9 of Table 3
gives an overview of the ratios between kV-Chest1 respective kV-Chest2 versus kV-MV-CBCT.
Fig 2. Setup and layout of different measurement positions of (a) inhomogeneous thorax phantom for patient
simulation (1: tumor in lower left lung, 2: left lung, 3: right lung, 4: upper periphery, 5: spinal cord, 6: body
center), and (b) CT dose body phantom for QA purposes.
https://doi.org/10.1371/journal.pone.0187710.g002
Table 2. Absolute dose correction factors for kV- and MV-energy, based on AAPM TG61 report and IAEA TRS 398, respectively, whereas the val-
ues for HVLBS and Q were calculated from the beam quality measurements.
kV-energy correction factors MV-energy correction factors
kV-Chest1-CBCT kV-Chest2-CBCT kV-MV-CBCT 6MV linac
HVLBS 7.01mm Al 7.63mm Al 5.57mm Al Q 0.6858
men
r
 water
air
 
water
1.0394 1.0417 1.0346 kQ 0,9894
PQ,cham 1.022 1.023 1.019 ND,w 1.0108 Gy/C
Psheath 1 1 1
Nk 8.757107 Gy/C
https://doi.org/10.1371/journal.pone.0187710.t002
Evaluation of kV-MV-CBCT dose exposure
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Among each other, the two clinical presets kV-Chest1 and kV-Chest2 differed mainly in the
applied nominal tube current (mA) and pulse duration (ms), see Table 1. Furthermore, the
bow-tie filter in kV-Chest2-CBCT also reduced imaging dose [41]. KV-Chest1 resulted in an
absolute dose of 31.26mGy in the tumor and 22.85mGy in the contralateral lung. For kV-
Chest2, these dose values were reduced by a factor of 3–4, resulting in 9.10mGy for the tumor
region and 5.22mGy for the organ at risk. Dose output was slightly inhomogeneous distributed
around the phantom due to the fact that the phantom was positioned off-centered. The small-
est dose was detected in the spinal cord.
KV-MV-CBCT dose outputs lay in between the dose outputs of both kV-presets. Maximum
dose of kV-MV-CBCT was 22.88mGE at the left lung position. Minimum dose of 6.60mGE
was exposed to the contralateral lung. This was due to asymmetric dose distribution; organs
at risk could be spared. At the tumor position, dose output of the kV-MV approach was
20.51mGE, i.e. it was 34% smaller than kV-Chest1 and 2.25 times higher than kV-Chest2. The
largest difference of 3.3 times the dose output of the kV-Chest2-CBCT appeared at the position
of the spinal cord. Compared to the kV-Chest1-CBCT, however, kV-MV dose output was still
8% lower.
Fig 3. (a) HVL measurement results for all kV-dependent CBCT-presets, (b) PDD for MV beam quality determination, and (c)
simulation of 4MU distributed over a 100˚ gantry arc with the TPS.
https://doi.org/10.1371/journal.pone.0187710.g003
Evaluation of kV-MV-CBCT dose exposure
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CTDI quality assurance
The CTDIw was calculated following Eq 8. The resulting dose values for each of the five mea-
surement points as well as the final weighted CTDI are listed in Table 4. The MV-contribution
of the kV-MV-CBCT dose measurement results were converted to kV-equivalent dose by tak-
ing half of the MV dose value. This kV-equivalent MV dose was added to the kV-contribution,
resulting in the final absorbed kV-MV-CBCT dose output.
Dose comparison of kV-MV imaging vs. conventional CBCT. Among each other, the
clinical presets kV-Chest1 and kV-Chest2 differed in nominal dose output about a factor of 3.2,
Table 3. Absorbed dose for different presets in inhomogeneous thorax phantom (column 8), ratio between the imaging methods and reference
dose output kV-MV (D/Dref) (column 9), comparison of MV-contribution dose output between measured and calculated (TPS) absolute dose by per-
centage difference (column 3–5), and separate contributions of kV- and RBE-corrected MV absorbed dose to kV-MV-CBCT in columns 6+7 (GE:
Gray-equivalent with RBE = 2 for kV-dose contribution).
Position CBCT calculated (TPS): measured: final absorbed
dose
ratio vs.
kV-MVMV part percentaged difference
(%)
MV part MV part (kV-
equivalent)
kV part
1: tumor- lower left
lung
kV-MV 40.40
mGy
0.35 40.26
mGy
20.13 mGE 0.38
mGy
20.51 mGE 1.00
kV-Chest1 31.26 mGy 1.52
kV-Chest2 9.10 mGy 0.44
2: upper left lung kV-MV 44.90
mGy
0.45 45.10
mGy
22.55 mGE 0.33
mGy
22.88 mGE 1.00
kV-Chest1 32.00 mGy 1.40
kV-Chest2 9.13 mGy 0.40
3: right lung kV-MV 13.40
mGy
2.84 13.02
mGy
6.51 mGE 0.09
mGy
6.60 mGE 1.00
kV-Chest1 22.85 mGy 3.46
kV-Chest2 5.22 mGy 0.79
4: upper center kV-MV 37.30
mGy
1.74 37.95
mGy
18.98 mGE 0.13
mGy
19.10 mGE 1.00
kV-Chest1 23.06 mGy 1.21
kV-Chest2 6.21 mGy 0.33
5: spinal cord kV-MV 30.00
mGy
0.60 29.82
mGy
14.91 mGE 0.20
mGy
15.12 mGE 1.00
kV-Chest1 16.45 mGy 1.09
kV-Chest2 4.62 mGy 0.31
6: body center kV-MV 34.30
mGy
1.55 34.83
mGy
17.41 mGE 0.16
mGy
17.57 mGE 1.00
kV-Chest1 21.54 mGy 1.23
kV-Chest2 5.96 mGy 0.34
https://doi.org/10.1371/journal.pone.0187710.t003
Table 4. Determination of weighted CTDI for different CBCT-presets (GE: Gray-equivalent with RBE = 2 for kV-dose contribution) (columns 2, 3
and 5) and ratio between the imaging methods and reference dose output kV-MV (D/Dref) (columns 4 and 6).
Position kV-MV-CBCT kV-Chest1-CBCT ratio vs. kV-MV kV-Chest2-CBCT ratio vs. kV-MV
CTDIc 14.70 mGE 9.68 mGy 0.66 3.42 mGy 0.23
CTDIp, 0˚ 19.83 mGE 20.52 mGy 1.03 6.41 mGy 0.32
CTDIp, 90˚ 16.72 mGE 20.24 mGy 1.21 6.00 mGy 0.36
CTDIp, 180˚ 5.66 mGE 20.61 mGy 3.64 5.53 mGy 0.98
CTDIp, 270˚ 5.74 mGE 22.27 mGy 3.88 6.74 mGy 1.17
CTDIw 11.99 mGE 17.16 mGy 1.43 5.25 mGy 0.44
https://doi.org/10.1371/journal.pone.0187710.t004
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due to different tube current per pulse duration (mAs) and different filters (see Table 1),
which transmits to the different dose output. This difference is also seen in the comparison of
CTDIw: the measured weighted CT dose index for kV-Chest1 is 17.16mGy, and 5.25mGy for
kV-Chest2. The kV-MV weighted CT dose index was in between both clinical presets, with
CTDIw = 11.99mGE.
Discussion
While currently standard clinical kV-CBCT image acquisition for lung tumor position verifi-
cation takes about 3-4min in repeated breath-hold, our in-house developed and recently fully
established automatic ultrafast combined kV-MV-CBCT method enables imaging within only
one single breath-hold of 15s [16,17], providing promising approach for DIBH-patients suffer-
ing from lung cancer [8].
For clinical implementation of a novel imaging technique, feasibility has to be evaluated
regarding fulfillment of sufficient image quality for registration within 1mm and small dose
exposure compared to prescribed dose. Excellent registration accuracy of combined kV-MV-
CBCT was recently reported [17]. A remaining issue, however, is the dose exposure to the
patient. The MV-contribution of kV-MV-CBCT could be a critical dosimetric issue and there-
fore merits comparison with standard kV-CBCT.
The kV-MV dose output in this study was composed as a sum of the kV-contribution, and
the MV-contribution converted into kV-equivalent dose by considering changes in RBE
between both kV- and MV-energies. Following recommendations in literature [26,32], a con-
servative RBE of 2 vs. 1 was chosen for kV vs. MV dose.
A hallmark of kV-MV-CBCT is its asymmetric dose distribution, due to the limited gantry
angle rotation of 90˚. The maximum dose was in the left lung where the tumor was located
and the kV- and MV-contributions overlapped. Healthy tissue such as the contralateral lung
could therefore be spared; kV-MV dose in the healthy right lung was thus 2/3 lower than the
clinical preset kV-Chest1. Compared to latest available kV-Chest2, the kV-MV-CBCT dose is
up to 3.3 times higher, whereas the dose value in the contralateral lung was almost the same,
due to homogeneous distribution of kV-Chest2.
In 2015, Alaei and Spezi [42] published a detailed review of more than 500 publications on
both kV and MV-CBCT imaging dose. Most of the presented studies performed dose measure-
ments with the clinical kV-CBCT presets provided by the manufacturers. They either measured
CTDI [20,34,43], or tried to estimate imaging dose to the patient by phantom measurements
[44,45] or Monte Carlo simulations [37,46]. However, previous studies did not consider the dif-
ferent RBE of kV imaging [43], neither in their dose calculations, nor in their risk analysis. Not
only physical dose but also its biological relevance should therefore be considered in any com-
parison. The trade-off between benefits of frequent imaging and its downside, additional dose
to non-target tissues, is currently discussed [43,47,48]. All in [42] reviewed fractional dose val-
ues vary strongly due to different methods and phantoms, but common kV dose values are
reported to be between 10-50mGy for internal organs and up to 70mGy for skin. For linac-
based MV-CBCT, doses of 100-150mGy per fraction are typical if the 6MV therapeutic beam is
used, and is therefore usually accounted for in treatment planning [6,7]. The MV-CT installed
on a Hi-Art Tomotherapy unit however uses 3.5MV for imaging and results in the range of
20mGy for CTDIw [49]. All these values however do not consider different RBE for kV- and
MV-energy range. In 2015, Liu et al. [50] published a theoretical approach to combine kV- and
MV-CBCT imaging focusing on image quality only with their fractional imaging doses of 0.5-
2Gy, making a clinical implementation impossible at this stage of research. The non-RBE cor-
rected dose output of our novel kV-MV-CBCT implementation, however, already produced an
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acceptable range from 13.11–45.43mGy in inhomogeneous thorax phantom measurements. In
case of different wear of magnetron and electron gun, an MV output of 5MU would lead to a
dose output between ~16-57mGy. In our approach, exceeding 5MU per 90˚ arc (+ cone-angle)
would not be possible because of hard-coded interlock in our automated kV-MV workflow
[14,16].
Therefore it can be concluded that not only the dose output results of our clinical CBCT-
presets kV-Chest1 and kV-Chest2 are in close agreement with the above-mentioned literature
[42], but also kV-MV-CBCT. The MV-contribution is relatively small compared to MV-CBCT
dose outputs in literature [6,42] or standard EPID verifications (~4MU) and does not have to
be considered in treatment planning, because we triggered the MV-output to low dose and our
imaging time is reduced to only 15s [14,16]. Furthermore, kV-MV could reduce dose exposure
to sensitive patient skin due to the MV-build-up effect.
Eventually, the most important aspect of the dosimetric properties of kV-MV-CBCT is that
the determined imaging doses of approximately 22mGE/ 45mGy remain negligible compared
to the prescribed dose, particularly for SBRT [43].
Conclusions
This comparison study demonstrated that the dosimetric properties of kV-MV-CBCT were in
agreement with common clinically established imaging techniques, whereas biologically effec-
tive exposure to healthy tissue was reduced. Together with the previously published report on
registration accuracy with kV-MV-CBCT [17], this dosimetric study demonstrates that
kV-MV-CBCT fulfills all necessary requirements for imminent clinical implementation.
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